BIOLOGY
纳安生物
Research area
Current Landscape of Cancer Treatment
Conventional cancer therapies primarily include surgery, chemotherapy, and radiotherapy. While chemotherapy and radiotherapy effectively eliminate tumor cells, they also significantly damage healthy cells. Targeted therapy, which focuses on cancer-specific molecular targets, directs drugs or antibodies specifically against cancer cells and their components. Although this approach minimizes harm to normal cells, it still faces limitations including immunogenicity, tumor heterogeneity, tumor microenvironment complexities, and patient drug resistance.
The ADC Breakthrough
The strategic combination of targeted drugs and chemotherapeutic agents has led to the development of a new generation of anticancer therapeutics: Antibody-Drug Conjugates (ADCs). These "biological missiles" utilize antibody targeting precision to deliver potent cytotoxic payloads directly to tumor tissues. The targeted release mechanism significantly reduces the systemic toxicity associated with conventional chemotherapy.
Nanolattix's ADC Innovation
Since its founding in 2018, Nanolattix Biologics has specialized in ADC anticancer drug development. ADCs uniquely combine the precision of targeted therapy with the potency of chemotherapy, establishing them as a revolutionary approach in oncology. The company's lead candidate, T320-ADC, demonstrates exceptional targeting capability against multiple malignant solid tumors. With complete intellectual property protection, patented technology, and optimized drug-like properties, T320-ADC represents a significant advancement in China's ADC landscape. This innovation not only addresses a critical gap in domestic ADC development but also elevates China's global competitiveness in the field. Nanolattix has established a robust biologics R&D platform supporting multiple advancing pipelines.
